THE CONCEPT OF VALUE-BASED HEALTHCARE: OPPORTUNITIES FOR DRUG PRICING


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

The paper reviews methodological approaches to value-based pricing (VBP), within which the principles of determining the values of drugs and converting the resulting value into a price. At the value determination stage, the investigators identify two main approaches: 1) to use the indicator the number of years of life in terms of its quality (quality-adjusted life-year (QALY)) as a value criterion and 2) to determine multicriteria values. On this evidence, an approach to calculating the drug price is subsequently determined. The classic approach is to use the cost-effectiveness analysis and the established willingness-to-pay threshold for an additional QALY; however, it does not make it possible to take into account all aspects of value and requires that cost-effectiveness should be used as the main driver in making a reimbursement decision. The alternative approaches are to determine the willingness to pay per unit of aggregate value (taking into account multiple criteria) using the net monetary benefit method or establishing a premium system in terms of a drug's value level. Currently, only the United Kingdom fully uses cost-effective VBP, while other countries employ its elements.

全文:

受限制的访问

作者简介

Valeriya Lemeshko

Center of Healthcare Expertise and Quality Control, Ministry of Health of the Russian Federation; I.M. Sechenov First Moscow State Medical University (Sechenov University)

Email: lera.lemeschko@yandex.ru
Head Deputy of the Department of Methodological Support of Comprehensive HTA; post graduate student of the Department of Pharmacology 10, Khokhlovsky Lane, Build. 5, Moscow 109028, Russian Federation; 8, Trubetskaya St., Build. 2, Moscow119991, Russian Federation

Nuriya Musina

Center of Healthcare Expertise and Quality Control, Ministry of Health of the Russian Federation; Saint Petersburg State Chemical Pharmaceutical University

Email: nuriyamusina@gmail.com
Associate Professor of the Department of Management and Farmacoeconomics; Head of the Development and Communications Department 10, Khokhlovsky Lane, Build. 5, Moscow 109028, Russian Federation; 14, Prof. Popov St., Saint Petersburg 197376, Russian Federation

参考

  1. Porter M.E., Lee T.H. From Volume to Value in Health Care: The Work Begins. JAMA. 2016; 316 (10): 1047-8. doi: 10.1001/jama.2016.11698
  2. Garrison L.P., Towse A. Value-Based Pricing and Reimbursement in Personalised Healthcare: Introduction to the Basic Health Economics. J. Pers. Med., 2017; 7 (3): 10. doi: 10.3390/jpm7030010
  3. Garner S., Rintoul A., Hill S.R. Value-Based Pricing: L'Enfant Terrible?. Pharmacoeconomics, 2018; 36 (1): 5-6. doi: 10.1007/s40273-017-0567-4
  4. Moreno S.G., Ray J.A. The value of innovation under value-based pricing. J. Mark. Access. Health Policy. 2016; 4. doi: 10.3402/jmahp.v4.30754.
  5. Jommi C., Armeni P., Costa F. et al. Implementation of value-based pricing for medicines. Clinical therapeutics, 2019; 42 (1): 15-24. doi: 10.1016/j.clinthera.2019.11.006
  6. Kanavos P., Manning J., Taylor D. et al. Implementing value-based pricing for pharmaceuticals in the UK. London: 2020 health. 2010.
  7. Keckley P.H., Snyder G. Value Based Pricing for Pharmaceuticals, Implications of the Shift from Volume to Value. Deloitte Center for Health Solutions, 2012.
  8. Sussex J., Towse A., Devlin N. Operationalizing value-based pricing of medicines: a taxonomy of approaches. Pharmacoeconomics. 2013; 31: 1-10. doi: 10.1007/s40273-012-0001-x
  9. Net Monetary Benefit [online]. York; York Health Economics Consortium; 2016. [Electronic resource]. Access mode: https://yhec.co.uk/glossary/net-monetary-benefit (circulation date: 15.06.2020).
  10. Paulden M. Recent amendments to NICE's value-based assessment of health technologies: implicitly inequitable? Expert.Rev. Pharmacoecon. Outcomes. Res., 2017; 17 (3): 239-42. doi: 10.1080/14737167.2017.1330152
  11. National Institute of Health and Clinical Excellence. Changes to NICE drug appraisals: what you need to know. [Electronic resource]. Access mode: https://www.nice.org.uk/ news/feature/changes-to-nice-drug-appraisals-what-you-need-to-know
  12. National Institute of Health and Clinical Excellence. Centre for health technology evaluation. Consultation Paper Value Based Assessment of Health Technologies. [Electronic resource]. Access mode: https://www.nice.org.uk/Media/Default/ About/what-we-do/NIC
  13. Омельяновский В.В., Никитина А.В., Лемешко В.А., Хачатрян Г.Р. Лекарственное обеспечение и оценка технологий здравоохранения во Франции. ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология. 2020; 13 (1): 71-83. doi: 10.17749/2070
  14. Wenzl M., Paris V. Pharmaceutical reimbursement and pricing in Germany. 2018.
  15. Rahmenvereinbarungnach § 130b Abs. 9 SGB V. [Electronic resource]. Access mode: https://www.gkv-spitzenver-band.de/media/dokumente/krankenversicherung_1/arzneimittel/ rahmenvertraege/pharmazeutische_unternehmer/ Rahmenvereinbarung_130b_Abs9 SGB_V_2016.pdf
  16. Горкавенко Ф.В., Омельяновский В.В., Безденежных Т.П., Хачатрян Г.Р. Оценка технологий здравоохранения и система лекарственного возмещения в Италии. ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология. 2019; 12 (2): 156-64. doi: 10.17749/2070-4909.2019.12.2.156-164

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Russkiy Vrach Publishing House, 2020
##common.cookie##